今开:41.97 | 昨收:41.84 |
最高:42.72 | 最低:41.59 |
涨停价:0.0 | 跌停价:0.0 |
总市值:6.187163783E9 |
产业链观察04-08 20:11
#药闻简讯# 2024年4月7日,$伊奥尼斯制药(IONS)$ 公布了领先的独立研究药物 olezarsen 用于治疗家族性乳糜泻综合征(FCS)成人患者的 3 期平衡研究的全部结果。 每月剂量为80毫克的olezarsen达到了主要终点,即在6个月时显著降低基因验证的FCS患者的甘油三酯(TGs)。 此外,奥利沙砷还显示出甘油...查看全文
伊奥尼斯制药(IONS)02-13 19:15
$伊奥尼斯制药(IONS)$ SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals Accession Number: 0001193125-24-032788 Act: 34 Size: 48 KB 网页链接查看全文
伊奥尼斯制药(IONS)02-03 06:25
$伊奥尼斯制药(IONS)$ 144 Report of proposed sale of securities Accession Number: 0000874015-24-000087 Act: 33 Size: 4 KB 网页链接查看全文
伊奥尼斯制药(IONS)02-03 06:35
$伊奥尼斯制药(IONS)$ 144 Report of proposed sale of securities Accession Number: 0000874015-24-000091 Act: 33 Size: 6 KB 网页链接查看全文
伊奥尼斯制药(IONS)02-03 06:45
$伊奥尼斯制药(IONS)$ 144 Report of proposed sale of securities Accession Number: 0000874015-24-000094 Act: 33 Size: 7 KB 网页链接查看全文
伊奥尼斯制药(IONS)02-03 09:05
$伊奥尼斯制药(IONS)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0000874015-24-000110 Size: 9 KB 网页链接查看全文
伊奥尼斯制药(IONS)03-05 08:15
$伊奥尼斯制药(IONS)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0000874015-24-000122 Size: 4 KB 网页链接查看全文
伊奥尼斯制药(IONS)02-22 05:45
$伊奥尼斯制药(IONS)$ 10-K Annual report [Section 13 and 15(d), not S-K Item 405] Accession Number: 0000874015-24-000116 Act: 34 Size: 19 MB 网页链接查看全文
伊奥尼斯制药(IONS)02-14 23:15
$伊奥尼斯制药(IONS)$ SC 13G Statement of acquisition of beneficial ownership by individuals Accession Number: 0001897612-24-001128 Act: 34 Size: 6 KB 网页链接查看全文
伊奥尼斯制药(IONS)02-03 09:05
$伊奥尼斯制药(IONS)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0000874015-24-000106 Size: 7 KB 网页链接查看全文
智通财经APP获悉,9月27日,Ionis制药(IONS.US)(Ionis Pharmaceuticals)宣布,反义寡核苷酸疗法olezarsen在治疗家族性乳糜微粒血症综合征(FCS)患者的3期临床试验中达到主要疗效终点。与安慰剂相比,6个月时olezarsen(80 mg每月一次)组... 网页链接
智通财经APP获悉,百健(BIIB.US)和Ionis Pharmaceuticals(IONS.US)周一宣布,将终止C9orf72相关肌萎缩侧索硬化症(ALS)的候选药物BIIB078的临床开发。受此消息影响,百健盘前跌0.18%,Ionis跌4.01%。 两家公司表示,该决定是根据来自106... 网页链接
智通财经APP获悉,阿斯利康(AZN.US)周二表示,该公司已经与Ionis制药公司(IONS.US)就Eplontersen(以前称为Ionis-trr-lrx)达成了一项新的全球开发和商业化协议。 两家公司将在美国联合开发Eplontersen并将其商业化,而阿斯利康将在除拉丁... 网页链接
ARK基金于6月28日买入Coinbase(COIN.O)、Ionis制药(IONS.O)等股,卖出哔哩哔哩(BILI.O)、Raven Industries(RAVN.O)等股。 网页链接
$伊奥尼斯制药(IONS)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0000874015-24-000138 Size: 9 KB 网页链接
$伊奥尼斯制药(IONS)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0000874015-24-000139 Size: 10 KB 网页链接
$伊奥尼斯制药(IONS)$ 144 Report of proposed sale of securities Accession Number: 0000874015-24-000135 Act: 33 Size: 4 KB 网页链接
$伊奥尼斯制药(IONS)$ 144 Report of proposed sale of securities Accession Number: 0000874015-24-000134 Act: 33 Size: 4 KB 网页链接
$伊奥尼斯制药(IONS)$ 8-K Current report, items 8.01 and 9.01 Accession Number: 0001140361-24-018449 Act: 34 Size: 203 KB 网页链接
$伊奥尼斯制药(IONS)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0000874015-24-000133 Size: 5 KB 网页链接
$伊奥尼斯制药(IONS)$ 3 Initial statement of beneficial ownership of securities Accession Number: 0000874015-24-000132 Size: 3 KB 网页链接
$伊奥尼斯制药(IONS)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0000874015-24-000122 Size: 4 KB 网页链接
$伊奥尼斯制药(IONS)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0000874015-24-000124 Size: 4 KB 网页链接
$伊奥尼斯制药(IONS)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0000874015-24-000125 Size: 4 KB 网页链接